Arvinas doses first ARV-6723 patients as EU trial-advice service goes permanent

What happened

On 3 November 2026, Arvinas reported Q3 2026 results and said it has dosed the first patients with ARV-6723, its HPK1 degrader. The molecule is in a Phase 1/2 trial in solid tumours. The company also reported cash of $558.9 million, which it says lasts into the second half of 2028, and said it plans EU and UK filings for ARV-102 in progressive supranuclear palsy (PSP).

The records give us the headline facts and little else. They do not say how many patients have been dosed, at what dose levels, in which tumour types, or in which countries. They also do not say when the ARV-102 filings are expected or what type of application they will be. Those gaps matter, and readers should not fill them with assumptions.

Why it matters for trial teams

The update combines an early-stage oncology programme with a company preparing regulatory submissions in a neurodegenerative indication. That is a typical mix of work for a mid-sized developer, and it puts load on several functions at once: early-phase operations, data quality, and regulatory writing for the planned filings.

The cash runway statement is also operationally relevant. A runway into 2H 2028 means the company can in principle fund the Phase 1/2 programme and the preparation of the ARV-102 filings without needing new capital in the near term. The records do not say what the runway assumes, so it should not be read as a commitment to specific trial timelines. For CROs, sites and vendors, a stated runway is a reasonable input to planning conversations, but not a guarantee of study scope.

Regulatory context: the EU is formalising trial advice

The same day, ACT EU announced that its clinical trial application advice pilot becomes a permanent service from January 2027. The pre-submission advice procedure is for sponsors using CTIS, the EU's Clinical Trials Information System. It has run as a pilot since 2024 and will continue beyond 2026 with updated guidance and templates.

The records do not describe the procedure's scope, timelines or eligibility criteria, so sponsors should read the updated guidance before building it into plans. The direction is still clear. The EU is making structured, early dialogue on trial applications a routine option rather than an experiment. Sponsors running first-in-human or multinational oncology studies, as Arvinas's Phase 1/2 programme may be, are the obvious audience. The records do not say whether Arvinas plans to use the service.

A related but separate development concerns marketing authorisation rather than trials. Austria's BASG reports that the CMDh has revised its validation advice, updated request templates for reference member states, and clarified which national requirements actually block the start of a mutual recognition or decentralised procedure. The change lets the RMS start procedures when concerned member states fail to answer validation queries. It does not concern clinical trials directly. It is useful background for any sponsor, such as one planning EU filings, that expects to run a multi-country authorisation route. The records do not say which route Arvinas intends to use for ARV-102.

Adjacent signals: diagnostics and supply quality

Two other records add colour, though neither involves Arvinas. Allarity Therapeutics won its first paid contract for a new CLIA-certified laboratory services business. The Danish-based company will develop and validate a European biotech's precision oncology predictive device for US use, after its Hørsholm lab gained CLIA certification in July. For oncology sponsors, it is a reminder that predictive or selection tools tied to a trial or a future product need their own validation and laboratory-quality pathway. The records give no details on the device or the client.

Health Canada, meanwhile, has issued a Type I recall of a single lot of Marcan Pharmaceuticals' Cyclophosphamide for Injection USP 1000 mg after particulate matter was found. It is a Canadian action on one lot, and the records do not link it to any trial. It still illustrates a point trial teams should keep in view: sterile injectable quality problems can affect oncology sites, and sponsors and sites need a clear route for acting on recalls.

What to watch

Several unknowns will determine how much this news matters. For ARV-6723, the key questions are the trial's design, its geographic footprint and its first data, none of which the records provide. For ARV-102, the questions are the timing and form of the planned EU and UK filings. For the EU system, watch the updated ACT EU guidance and templates ahead of January 2027, and see whether sponsors adopt the advice service in practice.

Until more is disclosed, treat Arvinas's update as a status report: a first-in-human oncology start, a funded runway and filing intentions, with detail still to come.